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BACKGROUND: The use of opioid medications to
manage chronic pain is complex and challenging,
especially in primary care settings. Medication con-
tracts are increasingly being used to monitor patient
adherence, but little is known about the long-term
outcomes of such contracts.
OBJECTIVE: To describe the long-term outcomes of a
medication contract agreement for patients receiving
opioid medications in a primary care setting.
DESIGN: Retrospective cohort study.
SUBJECTS: All patients placed on a contract for opioid
medication between 1998 and 2003 in an academic
General Internal Medicine teaching clinic.
MEASUREMENTS: Demographics, diagnoses, opiates
prescribed, urine drug screens, and reasons for con-
tract cancellation were recorded. The association of
physician contract cancellation with patient factors
and medication types were examined using the Chi-
square test and multivariate logistic regression.
RESULTS: A total of 330 patients constituting 4% of
the clinic population were placed on contracts during
the study period. Seventy percent were on indigent care
programs. The majority had low back pain (38%) or
fibromyalgia (23%). Contracts were discontinued in
37%. Only 17% were cancelled for substance abuse
and noncompliance. Twenty percent discontinued con-
tract voluntarily. Urine toxicology screens were
obtained in 42% of patients of whom 38% were positive
for illicit substances.
CONCLUSIONS: Over 60% of patients adhered to the
contract agreement for opioids with a median follow-up
of 22.5 months. Our experience provides insight into
establishing a systematic approach to opioid adminis-
tration and monitoring in primary care practices. A
more structured drug testing strategy is needed to
identify nonadherent patients.
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INTRODUCTION
Chronic pain management is complex and is complicated by
substantial psychological and functional impairment that can
have a profound effect on quality of life. More than 75 million
Americans suffer from some form of chronic pain that is
unrelated to cancer,
1 and the number of these patients
followed in primary care practices is rising.
2,3 Unfortunately,
there is uncertainty on how to best manage these patients
because the available research in this area is limited to reports
of surveys and uncontrolled case series, largely from specialty
pain clinics.
5,7,8 Few studies have examined the management
of chronic pain in primary care settings.
1,3,4
Opioid medications are known to be effective in relieving
chronic pain and can improve mood and functional status as
well.
5,6 Research suggests that patients with chronic noncan-
cer pain can achieve satisfactory analgesia by using a stable
(non-escalating) dose of opioids with a minimal risk of
addiction.
10 Still, providers are cautious about prescribing
opioids owing to concern about their addictive properties and
side-effects, and concern about regulatory sanctions.
7–9
As care of patients with chronic pain in the primary care
setting increases, monitoring these patients for adherence to
treatment plans, response to medication, and development of
addiction has become critical.
9 A practical, standardized
approach to prescribing opioids is needed in all medical
settings, and particularly in primary care. Key organizations
have published consensus statements and guidelines to assist
physicians in prescribing opioids.
11–14 Use of a medication
contract agreement is one method that might improve patient
buy-in and monitor adherence to treatment plans.
15 A con-
tract or a partnership agreement is defined as an “explicit
bilateral commitment to a well-defined course of action”.
16
Contracts are widely used in the chronic administration of
potentially abusable drugs and behavior-linked problems.
17,18
Many academic pain management centers use an opioid
contract as part of their standard practice, and some of their
benefits and limitations have been described in these set-
tings.
19,20 However to date, there has been little exploration of
long-term contract use in improving adherence to chronic pain
therapy, reasons for discontinuation of contracts, or its use in
primary care practices.
19,21
In the current study, we describe a 5-year experience using
opioid contracts for chronic pain management in a large
academic primary care practice. We determined the demo-
graphics of enrolled patients, chronic pain diagnoses, types of
opioid medications prescribed, use of urine drug screens for
monitoring use of illicit substances, and reasons for discon-
tinuation of contract. We also looked at patient adherence to
Received May 2, 2006
Revised November 7 2006
Accepted November 13, 2006
Published online January 5, 2007
485contract agreements using a definition adapted from the pain
literature,
9,19 which we defined as patients receiving stable
doses of contracted medications at prescribed intervals and
adhering to the conditions of the contract agreement.
STUDY METHODS
This study covers the period January 1, 1998 to December 31,
2003 in the General Internal Medicine Clinic at the Medical
College of Wisconsin, an urban academic center and training
site for Internal Medicine residents. During the study period
the clinic had 8,644 enrolled patients. Ten board certified
Internists and over 30 residents practiced at the site. The
study protocol was approved by the Institutional Review Board
at the Medical College of Wisconsin.
In 1998, the faculty practice group initiated a provider–
patient agreement or medication contract protocol for patients
started on long-term opioid medications for chronic pain. In
2000, by consensus of the faculty providers, this method
became standard practice. All physicians including residents
participated and were trained on use of the contract. Patient
eligibility for a contract was determined by the primary
provider. In general, if long-term opioid therapy was initiated,
patients were asked to sign the medication contract agree-
ment. Monthly prescriptions were then provided to the patient.
Drug selection and dosing were determined by the physician.
Patients who refused to sign a contract were not eligible to
receive ongoing opioids through the practice. Whereas it is
possible that not all eligible patients were placed on contract,
every provider had a minimum of 2 patients enrolled in this
system. Nurses were trained to assist the Faculty-resident
teams in both implementation and ongoing follow-up care.
The medication contract is described in Figure 1 and
included both patient and physician responsibilities. In addi-
tion to the diagnosis, type and dose of medication prescribed, it
specified the conditions under which opioids would or would
not be prescribed and patient responsibilities. Random urine
drug screening would be performed if recommended by the
physician to monitor adherence and possible use of illicit
substances. Patients were informed that the contract would be
discontinued if patient responsibilities were not met. Respon-
sibilities of the physician and/or clinic staff included providing
monthly prescriptions on the due date, monitoring the effects
of therapy, and providing ongoing care.
Eligible patients included individuals with chronic non-
cancer pain, who signed a medication contract agreement for
long-term opioid medications during the study period. We
performed a retrospective chart review of eligible patients and
recorded patient demographics including age, sex, ethnicity,
and type of insurance. Insurance status was determined from
a billing database. If insurance changed, insurance type as of
July 2003 was used. Insurance was divided into 1) Medicare
only, 2) Medicaid with or without Medicare coverage, 3) county
“insurance” for patients at or below the poverty line, 4) private
insurance including preferred-provider, health maintenance
organization, and private fee-for-service insurance, and 5) no
insurance.
We recorded the etiologies of chronic pain for each patient.
Cases were more than 1 chronic pain condition was present,
the first recorded condition was selected as the principal
diagnosis. Conditions were organized by diagnosis, including
low back pain, degenerative joint disease (DJD), chronic
pancreatitis, sickle cell anemia, and fibromyalgia or pain in
multiple anatomic sites. A number of low volume diagnoses
including headache, autoimmune disorders, peripheral neu-
ropathy, avascular necrosis, phantom limb, and paraplegia
were pooled into a single category called miscellaneous causes.
We defined the type of opioids used by documentation in the
contract. They were categorized as long-acting, short-acting,
and combination therapy (combination of long- and short-
acting opioids). If the medication was changed in the contract,
the most recent prescription was used. To estimate the
duration of treatment with opioids, we used the date of onset
of the contract as time 0. The end date was any of the following:
1) the last day of the study period (i.e., Dec 31, 2003), or 2) date
the contract was terminated by the physician, or 3) last
recorded date of prescription, if the patient discontinued follow
up or did not receive any medications after July 1, 2003.
Urine toxicology screening (UTS) for monitoring therapy in
this population was identified by chart audit and review of all
laboratory studies from a computerized laboratory database.
The results of UTS were examined and categorized as negative,
positive for marijuana, cocaine, or positive for both. We chose
not to label urine devoid of the prescribed opioid as a positive
test, because of concerns of the accuracy of existing tests in
detecting therapeutic concentrations of several commonly
prescribed opioids.
We also determined the total number of contract cancella-
tions, and reasons for cancellation as documented on the
contract. The reasons for cancellation were adapted from prior
literature on screening for problematic prescription opioid use
22,23 and information from our charts. They were categorized
as: 1) positive UTS for cocaine and or marijuana, 2) prescrip-
tion opioid abuse, which included procurement of opioids from
multiple sources, prescription forgery, and use of opioids other
than that prescribed, 3) contract rules violation (e.g., missed
appointments, missed UTS and requests for early refills), and
4) other, including transfer of care to specialist. Cancellations
in categories 1–3 were considered physician initiated cancella-
tions in all analyses.
DATA ANALYSIS
The data were entered into a Microsoft Excel database and
analyzed using SAS version 8 statistical software. Descriptive
analysis of the data was used to summarize the demographic
characteristics of the patient sample, chronic pain diagnoses,
a n dt y p eo fo p i o i du s e da n dd u r a t i o no ft r e a t m e n t .T h e
percentage of patients whose contracts were cancelled and
the reasons for cancellation were determined. Differences in
diagnosis, type of medication used, and demographic factors
associated with contract cancellation were examined using the
Chi-square test for independence. Variables with p<0.1 were
examined in a multivariate logistic regression model using
backward regression to determine which predictors were
independently associated with contract cancellation.
RESULTS
A total of 332 patients were placed on contract during the
study period. Cancer patients (n=2) were excluded. The
486 Hariharan et al.: Contract Use in Chronic Pain Management JGIMFigure 1. Medication agreement for the treatment of chronic pain with controlled medications (opioid medication).
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representing 4% (330/8644) of our primary care practice.
On average, 78 patients enrolled in the contract each year
from 2001 to 2003. Median follow-up from initiation of opioid
contract was 646 days. Table 1 summarizes the demographic
data. The median age was 49 years; 52% were men. The
population was evenly divided between whites and blacks.
Seventy percent of the 330 patients were on indigent care
programs. Low back pain was the most commonly recorded
chronic pain diagnosis and was present in 37% of the patients.
The next most common disorder was fibromyalgia and pain in
multiple sites at 23%. Headache, DJD, and neuropathy were
less common.
Table 2 summarizes the various types of opioids prescribed.
These included long-acting opioids alone, short-acting opioids
alone, or a combination of both. The most common prescribing
pattern was combination therapy in 45%, followed by short-
acting alone (38%) (Table 2). The most prescribed opioid overall
was oxycodone/acetaminophen (22% of cohort). The most
prescribed long-acting opioid was sustained-release oxycodone.
A total of 140 (42%) patients had a UTS performed during
the course of the study. All physicians ordered toxicology
screens for at least 2 of their patients, with no differences in
the proportion of physicians’ panels tested. Patients who were
male (p=.044), younger (p=.02), who were taking long-acting or
combination therapy (p<.001), or who had sickle cell anemia
(p=.006) (compared with patients with low back pain ) were
more likely to receive testing. Patients with degenerative joint
disease were less likely to receive testing (p=.024). Among
those tested, 38% had an illicit substance detected (n=53).
Eighteen percent of patients tested were positive for cocaine,
14% for marijuana, and 6% were positive for both.
Over the 5 years 17% of contracts (n=54) were canceled by
the physician. Twenty percent of patients (n=65), discontinued
medications without cancellation. The most common reason
for physician cancellation was positive UTS in 50% (n=27) of
patients, followed by prescription drug abuse in 26% (n=14).
Only 7% (n=4) of patients were terminated for contract rules
violations, whereas 17% (n=9) were terminated for adminis-
trative reasons such as transfer of care to a specialist. No
contracts listed negative drug screen for prescribed opioids as
reason for cancellation.
We examined the association between patient or medication
factors and contract cancellation (Table 3). For these analyses,
contract cancellation was defined as positive UTS for cocaine
or marijuana, prescription drug abuse, or contract rules
violations (n=45 patients in total). It did not include adminis-
trative reasons for contract cancellation (n=9). Male sex and
combination therapy were both significantly associated with
contract cancellation in unadjusted analyses. There may have
been a trend toward less cancellation among older (>55)
patients, 6% of whom were cancelled as compared with 17%
of those aged 40–55 and 16% of those <40 (p=.069). There was
no difference in the number of patients canceled between users
of long-acting morphine (19% cancelled), long-acting oxycontin
(16%), nor reason for opioid use or insurance type.
When examined in analyses adjusted for patient age, male
sex remained associated with contract cancellation. In addi-
tion, compared with users of short-acting medications alone,
users of combination therapy had a greater chance of contract
cancellation. There was no difference between users of combi-
nation therapy and users of long-acting medications alone.
DISCUSSION
To our knowledge, this is the first study in a primary care
setting to describe long-term outcomes of a medication
Table 1. Characteristics of Patients Enrolled in the Medication
Contract and Overall Clinic Population
Patient
Characteristics
Percent of
contract population
(N=330)
Percent of overall clinic
population
(N=8644)
Sex
Male 52 38
Female 48 62
Race
White 50 59
Black 48 35
Other 2 6
Age
<40 yrs 33 24
40–55 yrs 42 34
>55 yrs 25 42
Insurance
Medicare Only 11 35
Medicaid (with
and without
Medicare)
49 16
County
insurance
21 12
Commercial 17 34
None 2 3
Diagnosis of chronic pain
Low back pain 37
Fibromyalgia
and/or pain in
multiple sites
23
Degenerative
joint disease
17
Chronic
pancreatitis
6
Sickle cell
anemia
5
Miscellaneous* 12
*Includes headache, auto-immune disorders, phantom limb, and periph-
eral neuropathy.
Table 2. Type of Opioids Prescribed
Opioid Medications N=330 Percent
Long-acting opioids alone 59 18
SR* oxycodone 24
Morphine long acting 17
Methadone 16
Fentanyl Patch 2
Short-acting opioids alone 124 38
Oxycodone/acetaminophen 74
Hydrocodone/ acetaminophen 22
Morphine 1
Acetaminophen with codeine 20
Propoxyphene+ acetaminophen 6
Hydromorphone 1
Combination therapy ** 147 45
SR* Oxycodone + short acting 70
Morphine long acting + short acting 51
Fentanyl + short acting 9
Methadone + short acting 17
*SR=Sustained release; **Combination of long-acting and short-acting
opioids.
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followed over 300 patients in a primary care setting, with
diverse demographic and clinical characteristics, for an aver-
age of 22.5 months.
Approximately 4% of our patient population was placed on
contract for chronic pain during the 5 years. We know of no
previous studies of patients followed long term on contract, so
other estimates of prevalence of opioid use available in the
literature are from computerized prescription records. Our
results were similar to the 3% prevalence estimated in a VA
study.
3
A key finding was that over 60% of patients remained on
contract during the study period, similar to average adherence
rates of 43 to 78% among patients receiving treatment for
chronic conditions noted in a recent review.
24 Physician-
initiated contract cancellations were observed in only 17% of
patients. Among those canceled, half were terminated for
positive toxicology screens and a quarter for prescription drug
abuse. More patients discontinued opioids voluntarily (20%)
than were canceled in our study. We found no associations
between contract cancellations and any patient characteristics
or pain diagnoses. Whereas there was an association between
use of combination therapy and contract cancellation, this
finding is subject to selection bias in this observational study,
and may reflect use of low doses of short-acting medications
alone in patients with milder pain.
Comparing our results to 2 previous studies
1,3 of opioid use
in single primary care systems we noted both similarities and
differences. Sixty-seven percent of patients were female, with a
median age of 53 years in the prior studies. In our study, the
median age was 49 years, and we had a higher proportion of
males. Low back pain was the most frequent pain diagnosis at
36% in our study, similar to other studies. In our study, 38% of
patients received short-acting opioids for their chronic pain,
with oxycodone/acetaminophen being the most commonly
prescribed at 22%. In Adams
1 and Reid,
3 short-acting opioids
were used in 60% and 46%, respectively, with oxycodone/
acetaminophen being the most common at 31%. However,
sustained-releaseoxycodone was the mostcommonly prescribed
long-acting opioid in our study compared to extended-release
morphine in the other 2 studies,
1,3 perhaps reflecting secular
trends and lack of a restricted formulary in most of our
population. Other reasons may include patient request or
pharmaceutical detailing. Physicians prescribed either long-
acting medications alone or combination therapy, as recom-
mended by multiple guidelines
11,13 for over 60% of patients.
Although many aspects of the contract system appear to
have been successful, primary care physicians often did not
monitor for contract adherence. Less than 45% (n=140) of
patients received UTS. There was no standardized protocol for
UTS in the clinic. UTS done at the discretion of the physician
was positive for illicit drugs in 38% (53/140) of tested patients,
and was the most frequent reason for contract cancellation. It
is likely that clinicians ordered UTS in patients they suspected
to be at higher risk for substance abuse. The ability of
physicians in general to recognize nonadherence to treatment
plans is poor.
24 In the absence of a clear guideline for drug
screening, it is possible that some abuse was not recognized.
Whereas drug screening is widely advocated, there is very little
data on its use in clinical settings.
25,26 Nevertheless, limited
data suggest that UTS may be more effective at identifying
nonadherent patients than monitoring behaviors alone or self
reports of drug use alone
27. Reports from 2 academic medical
centers with diverse population such as ours have noted 38%
3
and 32%
4 prevalence of substance misuse in their chronic
pain population, consistent with our study. Given that we did
not identify any clinical predictors of contract cancellation, a
more structured testing strategy with defined criteria for
interpretation of UTS would provide valuable information for
both diagnostic and therapeutic decision making regarding
substance misuse and contract discontinuation.
Our study has several limitations. First, it is a retrospective
analysis of care delivered in a single site and local culture and
trends may influence the nature of practice. Second, the
decision to prescribe opioids, the type of opioids, use of a
medication contract, and use of urine toxicology screening
were all at the discretion of the individual physicians in our
study. Our definition of contract adherence is also limited by
the lack of systematic drug testing done by the physicians in
our study. However, these limitations likely reflect real world
practice. We defined our chronic pain diagnoses by the first
listed diagnosis on the contract. Whereas this likely represents
the most severe pain, some patients had more than 1 diagnosis
listed, and therefore results of our comparisons by diagnosis
should be interpreted with caution. Finally, pain outcomes for
all patients, and in particular the outcomes for the 20% of
patients who discontinued contract without cancellation, are
unknown. It is possible that this reflects dissatisfaction with
Table 3. Association Between Patient Characteristics and
Physician-Initiated Contract Cancellation (Unadjusted and
Adjusted)
Patient Characteristics % Cancelled Unadjusted
P value
Adjusted
Odds Ratio
Sex
Male 18 0.015 1.9 (1.0, 3.9)
Female 9 -Reference
Age Group
<40 yrs 16 0.069 0.4 (0.1, 1.2)
40–55 yrs 17 0.4 (0.1, 1.1)
>55 yrs 6 -Reference
Insurance
Medicare Only 14 0.127
Medicaid (with
and without
Medicare)
16
County Insurance 8
Commercial 9
None 38
Diagnosis of Chronic Pain
Low Back Pain 13 0.658
Fibromyalgia and/
or pain in
Multiple sites
8
Degenerative Joint
Disease
15
Chronic Pancreatitis 14
Sickle Cell Anemia 20
Miscellaneous* 18
Drug Type
Short-acting
opioids
8 0.029 0.4 (0.2, 0.8)
Long-acting opioids 12 0.6 (0.2, 1.4)
Combination
Therapy**
19 -Reference
*Includes headache, auto-immune disorders, phantom limb, and periph-
eral neuropathy.
**Combination of long-acting and short-acting opioids.
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Conversely, it may simply reflect the transient nature of this
patient population. Despite the limitations, we believe that a
medication contract system has great potential as a systems-
based approach to management of pain in other academic
primary care practices that serve diverse patient populations.
In conclusion, we believe opioid contract use can provide
structure, support, and monitoring for long-term chronic pain
management in a large primary care practice. Our experience
can help provide insight in using such a tool more effectively.
Potential interventions should include standardized guidelines
for both pain assessment and monitoring therapy using pain
scales and urine drug testing for both opioids and illicit
substances. More research is needed to elucidate effective use
of UTS in the management of chronic pain, as improved
adherence monitoring may offer better control over pharmaco-
logical and psychological toxicity.
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